Golino Paolo, Loffredo Francesco, Riegler Lucia, Renzullo Elvira, Cocchia Rosangela
Division of Cardiology, Second University of Naples, Monaldi Hospital, Naples, Italy.
Curr Opin Investig Drugs. 2005 Mar;6(3):298-306.
Ischemic cardiovascular diseases represent the most common cause of mortality and morbidity in the western world, and atherothrombosis occupies a central role in their pathophysiology. Venous thrombi, which form under low shear conditions, are predominantly composed of fibrin and red cells, while arterial thrombi form under high shear conditions and are composed primarily of platelet aggregates held together by fibrin strands. Several successful strategies targeting specific steps in coagulation and platelet function or interaction have been developed to prevent or treat atherothrombotic disorders. Intense research is currently underway in an effort to develop more safe and effective compounds, such that novel antithrombotics are emerging to target specific steps in the coagulation cascade, as well as in pathways of platelet adhesion, activation and aggregation. This review will focus on the recent advances in research in this fast-evolving field.
缺血性心血管疾病是西方世界最常见的死亡和发病原因,动脉粥样硬化血栓形成在其病理生理学中起着核心作用。静脉血栓在低剪切力条件下形成,主要由纤维蛋白和红细胞组成,而动脉血栓在高剪切力条件下形成,主要由通过纤维蛋白链聚集在一起的血小板聚集体组成。已经开发出几种针对凝血和血小板功能或相互作用的特定步骤的成功策略来预防或治疗动脉粥样硬化血栓形成疾病。目前正在进行深入研究,以开发更安全有效的化合物,从而出现了针对凝血级联以及血小板粘附、激活和聚集途径中特定步骤的新型抗血栓药物。本综述将重点关注这一快速发展领域的最新研究进展。